- Home
- GOVX vs SYBX Comparison
GOVX vs SYBX Comparison
Compare GOVX & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- SYBX
- Stock Information
- Founded
- GOVX 2001
- SYBX N/A
- Country
- GOVX United States
- SYBX United States
- Employees
- GOVX N/A
- SYBX N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- GOVX Health Care
- SYBX Health Care
- Exchange
- GOVX Nasdaq
- SYBX Nasdaq
- Market Cap
- GOVX 17.1M
- SYBX 16.7M
- IPO Year
- GOVX N/A
- SYBX N/A
- Fundamental
- Price
- GOVX $2.57
- SYBX $1.41
- Analyst Decision
- GOVX Strong Buy
- SYBX Buy
- Analyst Count
- GOVX 5
- SYBX 4
- Target Price
- GOVX $14.20
- SYBX $15.50
- AVG Volume (30 Days)
- GOVX 3.6M
- SYBX 11.4K
- Earning Date
- GOVX 11-12-2024
- SYBX 11-12-2024
- Dividend Yield
- GOVX N/A
- SYBX N/A
- EPS Growth
- GOVX N/A
- SYBX N/A
- EPS
- GOVX N/A
- SYBX N/A
- Revenue
- GOVX $3,090,161.00
- SYBX $2,777,000.00
- Revenue This Year
- GOVX N/A
- SYBX N/A
- Revenue Next Year
- GOVX $565.58
- SYBX N/A
- P/E Ratio
- GOVX N/A
- SYBX N/A
- Revenue Growth
- GOVX N/A
- SYBX 292.23
- 52 Week Low
- GOVX $1.09
- SYBX $1.22
- 52 Week High
- GOVX $11.18
- SYBX $5.12
- Technical
- Relative Strength Index (RSI)
- GOVX 57.72
- SYBX 45.95
- Support Level
- GOVX $1.75
- SYBX $1.37
- Resistance Level
- GOVX $3.88
- SYBX $1.58
- Average True Range (ATR)
- GOVX 0.30
- SYBX 0.08
- MACD
- GOVX 0.15
- SYBX 0.00
- Stochastic Oscillator
- GOVX 44.60
- SYBX 14.32
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.